trending Market Intelligence /marketintelligence/en/news-insights/trending/OFcDf7kWGRKQLGZdQGSXUw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Trillium Therapeutics Inc. is cutting 17 jobs as part of a restructuring to focus its resources on the development of cancer treatments.

According to the company's Oct. 22 press release, the 40% reduction in staff is effective immediately, with 26 active employees remaining. The Mississauga, Ontario-based biotechnology company is looking for a partner for further development of its STING agonist program — a treatment that enhances the immune system to fight cancer tumors.

The company also plans to cut expenses through discontinuing its discovery research activities and through operational efficiencies.